GHRP-6 Dosage: Growth Hormone Research Protocol

Read this first

Dosage and protocol figures on this page are reproduced only from the matching PeptideDosages.com protocol. The 3 ml table is arithmetic based on those source amounts and the listed vial sizes. Educational research only — not instructions or medical advice.

Dosage chart

The dosage amounts and schedules below come only from PeptideDosages.com. Syringe-unit figures are mathematical conversions of those source amounts using exactly 3 ml of bacteriostatic water. Educational reference only — not instructions or medical advice.

GHRP-6 · 10 mg Vial

GHRP-6 is dosed at 100 mcg–300 mcg daily via subcutaneous injection in educational protocols.

Typical daily range: 300–900 mcg total (split into 3 doses with gradual titration).

Standard / Gradual Approach

Week/Phase	Dose per Injection (mcg)
Weeks 1–2	100 mcg
Weeks 3–4	200 mcg
Weeks 5–12	300 mcg

3 ml conversion

Select vial strength

5 mg + 3 ml = 1.67 mg/ml. Choose your vial strength to update the units below.

Source dose	U-100 syringe
100 mcg	6.0 units
200 mcg	12 units
300 mcg	18 units

Mixing note: growth-hormone secretagogues like GHRP-6 are commonly reconstituted with 0.5 ml of acetic acid solution topped up with 2.5 ml of bacteriostatic water (3 ml total). Educational reference only — not instructions.

Source chart on peptidedosages.com

Other growth hormone compounds

HexarelinSynthetic hexapeptide GH secretagogue HGH (somatropin, research reference)Recombinant 191-amino-acid human growth hormone IGF-1 LR3Modified insulin-like growth factor 1 analogue IGF-DESTruncated IGF-1 analogue missing the first three N-terminal residues IpamorelinSelective growth-hormone secretagogue (ghrelin mimetic)MGFSplice variant of IGF-1 produced by mechanically loaded muscle

All research protocols

GHRP-6: research background

What GHRP-6 Is

Growth hormone-releasing peptide-6 (GHRP-6) is a peptidyl growth hormone secretagogue (GHS) (PMID 9879640, PMID 30282322). It is a hexapeptide (PMID 9879640). Analogs of GHRP-6 have been synthesized, including azapeptide derivatives (PMID 32721647) and N-aminoimidazolidin-2-one (Aid) peptidomimetics (PMID 24697286). These analogs can help control peptide conformation or act as ligands for specific receptors (PMID 24697286, PMID 32721647). GHRP-6 is also referred to as a ghrelin mimetic due to its activity on the ghrelin receptor (PMID 19289567, PMID 38958606).

How It Is Thought to Work

GHRP-6 can act directly at the somatotroph, which are cells in the pituitary gland that produce growth hormone (PMID 8887178). As a ghrelin mimetic, GHRP-6 acts as an agonist of the ghrelin receptor (PMID 19289567). The ghrelin receptor is a seven-transmembrane (7-TM) receptor found to have increased expression in human carcinoma and heart failure (PMID 30282322). Some azapeptide analogs of GHRP-6 have been developed as selective ligands for CD36, a scavenger receptor involved in lipid uptake and atherosclerosis progression (PMID 32721647). GHRP-6 has also been observed to enhance the survival of renal tubular epithelial cells by activating the mTOR-P70 pathway in a laboratory setting (PMID 41327290).

Laboratory and Animal Studies Report

In male rats, GHRP-6 was primarily excreted in the bile after intravenous injection, showing a systemic plasma clearance (PMID 9879640). After intranasal application in rats, GHRP-6 showed moderate absorption, suggesting this route could be promising for systemic delivery (PMID 9879640). A self-assembling GHRP-6 peptide hydrogel was studied in a mouse model of acute kidney injury (AKI). This hydrogel treatment reprogrammed the metabolism of renal tubular epithelial cells, enriching spermidine, L-glutamine, and acetyl-CoA, and enhanced cell survival (animal study, PMID 41327290). In apoe-/- mice fed a high-fat, high-cholesterol diet, azapeptide analogs of GHRP-6 decreased lesion progression in the aortic arch and reduced aortic sinus lesion areas, indicating an anti-atherosclerotic effect. These effects were linked to a reduced ratio of inflammatory macrophages and lower plasma inflammatory cytokine levels, and were dependent on CD36 (animal study, PMID 32721647). In a rodent model of postoperative ileus (POI), a single dose of GHRP-6 (20 microg/kg) decreased the time to the first bowel movement (animal study, PMID 19289567). GHRP-6 reversed specific phenotypic effects of calorie restriction in mice related to gastric endocrine cell differentiation (animal study, PMID 38958606).

Human Evidence So Far

In short-statured children and adults with diagnosed growth hormone deficiency (GHD), intravenous GHRP-6 was used to evaluate pituitary GH reserve. Although a lower GH response to GHRP-6 was observed in GHD patients compared to normal children, there was considerable overlap (human study, PMID 8887178). A nearly complete blockade of GH response to GHRP-6, or combined GHRH plus GHRP-6, was found in patients with pituitary stalk transection, suggesting its potential as a diagnostic test for this condition (human study, PMID 8887178). A similar finding with combined GHRH plus GHRP-6 was observed in patients with adult-onset GHD, indicating its possible value in diagnosing this entity (human study, PMID 8887178).

Key Terms Explained

Pituitary GH reserve: The capacity of the pituitary gland to release growth hormone. Somatotroph: A cell in the pituitary gland that produces growth hormone. GHRH: Growth hormone-releasing hormone. Ghrelin receptor: A protein that binds ghrelin, influencing appetite and growth hormone release. CD36: A scavenger receptor that takes up modified lipoproteins, contributing to atherosclerosis. mTOR-P70 pathway: A signaling pathway involved in cell growth and metabolism. Renal tubular epithelial cells (TECs): Cells lining the kidney tubules, important for kidney function.

Studies cited in this section

Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency. — Journal of pediatric endocrinology & metabolism : JPEM, 1996 (PMID 8887178)
Atheroprotective and atheroregressive potential of azapeptide derivatives of GHRP-6 as selective CD36 ligands in apolipoprotein E-deficient mice. — Atherosclerosis, 2020 (PMID 32721647)
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation. — Journal of nanobiotechnology, 2025 (PMID 41327290)
N-aminoimidazolidin-2-one peptidomimetics. — Organic letters, 2014 (PMID 24697286)
Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. — Xenobiotica; the fate of foreign compounds in biological systems, 1998 (PMID 9879640)
Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. — European journal of medicinal chemistry, 2018 (PMID 30282322)
Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells. — The Journal of cell biology, 2024 (PMID 38958606)
Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. — The Journal of pharmacology and experimental therapeutics, 2009 (PMID 19289567)

Summarised from the PubMed abstracts listed above. Educational reference only — not medical advice or instructions.

Nearby in the protocol A–Z

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.

GHRP-6 dosage protocol